16 September 2026 editorial review · Item
SGLT2 / SGLT1-2 inhibitors (dapagliflozin, sotagliflozin): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: SGLT2 / SGLT1-2 inhibitors (dapagliflozin, sotagliflozin)
Scope and findings:
- Correct Q4 resubmission and Gulf heart-failure indications; remove speculative commercial motives and assertion ketone sensors solve all DKA risk. Score numbers unchanged.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.